Stocks in play: BioVaxys Technology Corp

Announced today that it has executed a binding Term Sheet with Procare Health Iberia, S.L of Barcelona, Spain, for exclusive marketing and distribution in the United States of Procare Health's leading patented product, Papilocare™, the world's first and only vaginal gel product with clinical evidences to prevent and treat HPV-dependent cervical lesions, and for Immunocaps®, an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions. As Immunocaps® is an OTC supplement, BioVaxys anticipates that regulatory approval is not required, allowing the rapid build out of sales channels and revenue generation from the product. BioVaxys Technology Corp shares C.BIOV are trading up $0.05 at $0.26.

Read:

• Highly Sought After Natural Ingredients Appearing in More Plant-Based Products Across North America

• Fresher, Healthier Food Options Coming Soon to an Airplane Tray Near You

• Airline Industry Wooing Back Customers with Enhanced, Healthier Menu Options

• Vegetarian and Vegan Fliers Winning Important Battle Over In-Flight Menu Options

• Mega Grocery Store Chains Listening to Customers’ Demands for Nutritious, Clean-Label Foods